ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.76
−1.12%Oct 18, 2026, 22:05 UTC
Zentalis Pharmaceuticals, Inc. announced that interim overall survival data from the DENALI Part 1b study were published in an abstract for an upcoming ESMO Congress 2026 presentation.
Aug 13, 2026, 20:01 UTC
Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and pre-funded warrants to purchase common stock.